Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Ginkgolides Meglumine Injection in Healthy Subjects
NCT02046031Phase 4Completed
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Ginkgo diterpene lactone meglumine in ischemic stroke, sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Feb 2014; status: completed.
02
Drugs
Ginkgo diterpene lactone meglumine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02046031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046031.